Alzheimer's Society blog

To understand the link between dementia and faulty blood vessels, we’re funding research into how blood flow in the brain relates to brain health and dementia. Find out what research we are funding in this area.

Donanemab has been licensed in the UK as a treatment for early-stage Alzheimer’s but is only available privately, not through the NHS. Here's what we know about this new Alzheimer's drug.

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this breakthrough Alzheimer's drug.